Cormorant Asset Management, LP Iterum Therapeutics PLC Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.7 - $5.99 $673,854 - $2.37 Million	-396,385 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$6.09 - $9.1 $11,662 - $17,426	-1,915 Reduced 0.48%	396,385 $2.73 Million
Q1 2019 May 15, 2019	SELL	$4.88 - $8.17 $330,385 - $553,125	-67,702 Reduced 14.53%	398,300 $3.2 Million
Q4 2018 Feb 14, 2019	SELL	$5.01 - $7.9 $54,939 - $86,631	-10,966 Reduced 2.3%	466,002 $2.34 Million
Q3 2018 Nov 14, 2018	SELL	$6.24 - $10.4 $143,719 - $239,532	-23,032 Reduced 4.61%	476,968 $3.2 Million
Q2 2018 Aug 14, 2018	BUY	$10.67 - $12.85 $5.34 Million - $6.43 Million	500,000 New	500,000 $5.45 Million

Ticker ITRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,233,400
Market Cap $15.9M
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract inf...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.